Clinical Trials Browser

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

100 enrolled

EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

285 enrolled

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Phase 1/2 Recruiting

56 enrolled

EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

70 enrolled

EndocrineNET

Advanced Lung Neuroendocrine Tumor

NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Phase 2 Recruiting

130 enrolled

CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04074135 2026-04-20

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Phase 2 Recruiting

740 enrolled

EndocrineGastrointestinalNET

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT06041516 2026-03-27

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Phase 1 Recruiting

70 enrolled

CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05237934 2025-11-12

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

Recruiting

300 enrolled

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Clinical Trials

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)